Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
51 pending office actions • 34 clients • 46 examiners • 30 art units • 0 of 51 (0%) have an AI response strategy ready
ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP focuses on the Biotechnology & Pharmaceuticals technology area. The firm has processed 1313 career applications, resulting in a resolved allowance rate pct of 83.02. This indicates a track record in securing allowances for complex life sciences inventions. The 83.02 percent allowance rate is a key indicator of the firm's results in securing patent rights. Practitioners can use this data to evaluate the firm's historical performance across its career filings.
Currently, the firm has 48 pending office actions. The average of 4.19 office actions per allowance serves as a measure of the typical prosecution duration and effort. This 4.19 average helps in setting expectations for the number of interactions required to reach a final decision. With 1313 applications in its history, the firm has a documented record of performance. The 48 pending office actions represent the current volume of active matters the firm is pursuing.
Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (8%) |
| §103 only | 9 (18%) |
| §102 only | 2 (4%) |
| §112 only | 8 (16%) |
| Double-patenting + other | 7 (14%) |
| Multi-statute (no §101) | 21 (41%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, TAEYOON | 3 | 51.5% | +52.1% |
| NOLAN, JASON MICHAEL | 2 | 66.5% | -27.8% |
| BLUMEL, BENJAMIN P | 2 | 70.8% | +30.5% |
| KATAKAM, SUDHAKAR | 2 | 74.7% | +23.3% |
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
| MOAZZAMI, NAGHMEH NINA | 1 | 72.0% | +49.3% |
| MARCSISIN, ELLEN JEAN | 1 | 34.5% | +49.3% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.2% | +43.4% |
| SCHMITT, BENJAMIN ALLYN | 1 | 8.3% | +40.0% |
| BLEDSOE, JOSHUA CALEB | 1 | 44.4% | +52.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259979 | DRUG ELUTING STENT | LYNCH, ROBERT A | 71d overdue |
| 18692995 | METHODS FOR PREPARING PEROVSKITE SOLAR CELLS (PSCS) AND THE RESULTING PSCS | KANG, TAE-SIK | 38d overdue |
| 18264079 | NOVEL PROCESS | NOLAN, JASON MICHAEL | 30d overdue |
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | KIM, TAEYOON | 15d overdue |
| 18262523 | DETECTING BETA-LACTAMASE ENZYME ACTIVITY | REGLAS, GEORGIANA C | 5d overdue |
| 17997439 | POROUS BONE SUBSTITUTION MATERIAL | BLANCO, JAVIER G | 4d overdue |
| 17641787 | ANTI-NUCLEOLIN AGENT-PEG-CONJUGATED NANOPARTICLES | MEJIAS, SAMANTHA LEE | 3d overdue |
| 17862892 | 3-D BIOPRINTING COMPRISING BIOLOGICALLY-RELEVANT MATERIALS AND RELATED METHODS | KIM, TAEYOON | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | KIM, TAEYOON | 15d overdue |
| 17862892 | 3-D BIOPRINTING COMPRISING BIOLOGICALLY-RELEVANT MATERIALS AND RELATED METHODS | KIM, TAEYOON | 12d |
| 18981938 | PHYSIOLOGICAL BIOMIMETIC CULTURE SYSTEM FOR HEART SLICES | ZHU, JIANJIAN | — |
| 18914680 | CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION | KIM, TAEYOON | — |
| 18849851 | BIOSYNTHESIS | MOAZZAMI, NAGHMEH NINA | — |
| 18728027 | METHOD FOR DETECTING A TAU PROTEIN IN A SALIVA SAMPLE | MARCSISIN, ELLEN JEAN | — |
| 18744060 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert | WEHBE, ANNE MARIE SABRINA | — |
| 18714448 | ARM-WORN ELECTROCARDIOGRAPHIC DEVICE AND METHOD FOR ELECTROCARDIOGRAPHIC SIGNAL MEASUREMENT | SCHMITT, BENJAMIN ALLYN | — |
| Art Unit | Apps |
|---|---|
| 1631 | 4 |
| 1641 | 3 |
| 1623 | 2 |
| 1672 | 2 |
| 3771 | 2 |
| 1682 | 2 |
| 1637 | 2 |
| 1656 | 2 |
| 1618 | 2 |
| 3796 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18981938 | PHYSIOLOGICAL BIOMIMETIC CULTURE SYSTEM FOR HEART SLICES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | ZHU, JIANJIAN | §103 | Non-Final OA | — | Pending | Dec 16, 2024 | |
| 18914680 | CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION | Cellectis | KIM, TAEYOON | §103§112DP | Non-Final OA | — | Pending | Oct 14, 2024 | |
| 18849851 | BIOSYNTHESIS | Plant Bioscience Limited | MOAZZAMI, NAGHMEH NINA | §112Other | Non-Final OA | — | Pending | Sep 23, 2024 | |
| 18728027 | METHOD FOR DETECTING A TAU PROTEIN IN A SALIVA SAMPLE | Gtinvent Limited | MARCSISIN, ELLEN JEAN | §103§112DP | Non-Final OA | — | Pending | Jul 10, 2024 | |
| 18744060 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert | Kriptic Pharmaceuticals Limited | WEHBE, ANNE MARIE SABRINA | §102§103DP | Non-Final OA | — | Pending | Jun 14, 2024 | |
| 18714448 | ARM-WORN ELECTROCARDIOGRAPHIC DEVICE AND METHOD FOR ELECTROCARDIOGRAPHIC SIGNAL MEASUREMENT | Demedar Spolka Z Ograniczona Odpowiedzialnoscia | SCHMITT, BENJAMIN ALLYN | 3796 | §103§112 | Non-Final OA | — | Pending | May 29, 2024 |
| 18701664 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18613613 | Silk Packaging Applications | Cambridge Crops, Inc,.D.B.A./Mori | BLEDSOE, JOSHUA CALEB | 1762 | §103§112Other | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18692995 | METHODS FOR PREPARING PEROVSKITE SOLAR CELLS (PSCS) AND THE RESULTING PSCS | Alliance for Energy Innovation, LLC | KANG, TAE-SIK | 1728 | §102§112 | Non-Final OA | 38d overdue | Pending | Mar 18, 2024 |
| 18598495 | BACTERIAL DELIVERY VEHICLE, PROCESS OF PRODUCTION AND USES THEREOF | Eligo Bioscience | KINSEY WHITE, NICOLE ERIN | 1672 | §112 | Final Rejection | — | Pending | Mar 07, 2024 |
| 18582939 | OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS | Institut Pasteur | BLUMEL, BENJAMIN P | §102§103§112 | Non-Final OA | — | Pending | Feb 21, 2024 | |
| 18424461 | PRODUCTION BACTERIAL CELLS AND USE THEREOF IN PRODUCTION METHODS | Eligo Bioscience | WANG, RUIXUE | §103§112DP | Non-Final OA | — | Pending | Jan 26, 2024 | |
| 18291050 | IL-10 INDUCING POLYPEPTIDES AND USES THEREOF | Enterome S.A. | KATAKAM, SUDHAKAR | §101§112 | Non-Final OA | — | Pending | Jan 22, 2024 | |
| 18571892 | METHODS FOR DIAGNOSING A CANCER- OR ANTIBIOTICS-INDUCED DYSBIOSIS AND THEIR USE FOR IMPROVING CANCER TREATMENT BY IMMUNOTHERAPY | INSERM | BERA, HENA RAKESHKUMAR | §101§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 | |
| 18530878 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY | Cellectis | NGUYEN, QUANG | 1631 | §102§103§112DP | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18556957 | NEW ANTI-MUC1 CARS AND GENE EDITED IMMUNE CELLS FOR SOLID TUMORS CANCER IMMUNOTHERAPY | Cellectis S.A. | WEN, SHARON X | 1641 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18551043 | LEFT ATRIAL APPENDAGE CLOSURE DEVICE WITH CATHETER-BASED DELIVERY | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | KHANDKER, RAIHAN R | 3771 | §103 | Final Rejection | — | Pending | Sep 18, 2023 |
| 18549286 | LENTIVIRAL VECTORS TARGETING ANTIGENS TO MHC-II PATHWAY AND INDUCING PROTECTIVE CD8+ AND CD4+ T-CELL IMMUNITY IN A HOST | Theravectys | KIM, YUNSOO | 1641 | §103§112DP | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18547471 | ANTIBODIES, FRAGMENTS OR DERIVATIVES SPECIFICALLY BINDING TO A PROTEIN ANTIGEN CAPABLE OF BINDING TO NUCLEIC ACIDS AND USES OF SAME | COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES | DRISCOLL, LORA E BARNHART | 3991 | §112 | Final Rejection | 25d overdue | Pending | Aug 22, 2023 |
| 18547256 | AN ARTIFICIAL TRAP-CAGE, ITS USE AND METHOD OF PREPARING THEREOF | UNIWERSYTET JAGIELLONSKI | SWIFT, CANDICE LEE | 1657 | §112 | Final Rejection | 4d overdue | Pending | Aug 21, 2023 |
| 18450060 | ULTRATHIN NANORIBBONS OF HIGHLY ANISOTROPIC LAYERED MATERIAL AND METHOD OF PRODUCTION | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | SHERMAN, ERIC SCOTT | 1736 | §102 | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18230278 | METHOD OF TREATMENT FOR HEART FAILURE USING STEM CELLS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | SCHUBERG, LAURA J | 1631 | §103 | Final Rejection | 34d | Pending | Aug 04, 2023 |
| 18264079 | NOVEL PROCESS | Artios Pharma Limited | NOLAN, JASON MICHAEL | 1623 | §103§112Other | Non-Final OA | 30d overdue | Pending | Aug 03, 2023 |
| 18262523 | DETECTING BETA-LACTAMASE ENZYME ACTIVITY | Universite Paris-Saclay | REGLAS, GEORGIANA C | 1651 | §102§103 | Final Rejection | 5d overdue | Pending | Jul 21, 2023 |
| 18259979 | DRUG ELUTING STENT | Sino Medical Sciences Technology Inc. | LYNCH, ROBERT A | 3771 | §102§112 | Non-Final OA | 71d overdue | Pending | Jun 29, 2023 |
| 18258271 | BIOMARKERS SIGNATURE(S) FOR THE PREVENTION AND EARLY DETECTION OF GASTRIC CANCER | Universite De Versailles Saint Quentin En Yvelines | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§103§112 | Final Rejection | — | Pending | Jun 19, 2023 |
| 17997439 | POROUS BONE SUBSTITUTION MATERIAL | Etat Francais Represente Par La Direction Centrale Du Service De Sante Des Armées | BLANCO, JAVIER G | 3774 | §102§103§112 | Final Rejection | 4d overdue | Pending | Jun 09, 2023 |
| 18002229 | Method for determining potency of chimeric antigen receptor expressing immune cells | Cellectis S.A. | HOWARD, ZACHARY C | 1674 | §102§112 | Final Rejection | 27d | Pending | May 23, 2023 |
| 18253977 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | Cellectis SA | SU-TOBON, QIWEN NMN | 1636 | §102§103 | Non-Final OA | 63d | Pending | May 23, 2023 |
| 18252438 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE AS ACTIVE INGREDIENT | Intract Pharma Limited | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | — | Pending | May 10, 2023 |
| 18040945 | Method for separation and/or detection and/or in vitro quantification of infectious compounds in biological material | Apoh-Technologies | HELLMAN, KRISTINA M | 1654 | §102§112 | Non-Final OA | — | Pending | Feb 07, 2023 |
| 18005284 | T-CELLS EXPRESSING IMMUNE CELL ENGAGERS IN ALLOGENIC SETTINGS | Cellectis S.A. | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | 26d overdue | Pending | Jan 12, 2023 |
| 18005146 | SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS | Theravectys | CHEN, STACY BROWN | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Jan 11, 2023 |
| 17997764 | BIOMIMETIC HEART TISSUE CULTURE SYSTEM | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | HENKEL, DANIELLE B | 1799 | §103§112 | Non-Final OA | — | Pending | Nov 02, 2022 |
| 17996733 | METHODS FOR TARGETED INSERTION OF EXOGENOUS SEQUENCES IN CELLULAR GENOMES | Cellectis S.A. | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17907324 | NEW THERAPEUTIC TARGETS WITH AN ANTI-INFLAMMATORY AND ANTI-INTERFERON EFFECT | INSERM | OTTON, ALICIA L | 1699 | §102 | Final Rejection | — | Pending | Oct 03, 2022 |
| 17862892 | 3-D BIOPRINTING COMPRISING BIOLOGICALLY-RELEVANT MATERIALS AND RELATED METHODS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | KIM, TAEYOON | 1631 | §103§112Other | Final Rejection | 12d | Pending | Jul 12, 2022 |
| 17789749 | COMPOSITION COMPRISING HYALURONIC ACID AND A POLYOL AND/OR CARBOXYMETHYL CELLULOSE | Ibsa Pharma SAS | CHO, DAVID H | 1693 | §112 | Final Rejection | 8d overdue | Pending | Jun 28, 2022 |
| 17780336 | METHOD OF LYOPHILIZATION OF A CRYOGENIZED CELLULAR COMPOSITION CONTAINING DISSOLVED GAS | Larena | MCKNIGHT, CIARA A | 1656 | §103 | Non-Final OA | — | Pending | May 26, 2022 |
| 17741686 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | JONES, DAMERON LEVEST | 1618 | §102§112Other | Final Rejection | — | Pending | May 11, 2022 |
| 17742173 | VITRO ISOLATION AND ENRICHMENT OF NUCLEIC ACIDS USING SITE-SPECIFIC NUCLEASES | Depixus | GRAY, JESSICA | 1682 | §102§103 | Final Rejection | 72d | Pending | May 11, 2022 |
| 17768002 | GENETICALLY MODIFIED HUMAN STEM CELL EXPRESSING A MUTANT HUMAN CYTOCHROME P450 2B6 PROTEIN AND ITS USE THEREOF IN THE TREATMENT OF CANCER | Sorbonne Universite | BURKHART, MICHAEL D | 1638 | §112 | Final Rejection | — | Pending | Apr 11, 2022 |
| 17761767 | A NOVEL COMPLEX FORMED BETWEEN THE FLAVIVIRAL NON-STRUCTURAL NS1 PROTEIN AND PLASMA LIPOPROTEINS | Institut Pasteur Du Cambodge | BLUMEL, BENJAMIN P | 1600 | §101§103§112 | Non-Final OA | — | Pending | Mar 18, 2022 |
| 17641787 | ANTI-NUCLEOLIN AGENT-PEG-CONJUGATED NANOPARTICLES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | MEJIAS, SAMANTHA LEE | 1618 | §102§103§112Other | Final Rejection | 3d overdue | Pending | Mar 09, 2022 |
| 17634373 | METHOD FOR IN VITRO PRODUCTION OF HYALINE CARTILAGE TISSUE | Vanarix SA | MARTIN, PAUL C | 1653 | §103 | Final Rejection | — | Pending | Feb 10, 2022 |
| 17620819 | ANTHRACYCLINE DERIVATIVES | Almac Discovery Limited | HOPKINS, SAMANTHA LAKE | 1641 | §103§112Other | Final Rejection | — | Pending | Dec 20, 2021 |
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | INSERM | KIM, TAEYOON | 1631 | §102§103 | Final Rejection | 15d overdue | Pending | Jul 13, 2021 |
| 17268596 | METHOD FOR CONJUGATION OF BIOMOLECULES AND NEW USE OF GOLD DONOR FOR BIOMOLECULAR COMPLEX FORMATION | UNIWERSYTET JAGIELLONSKI | SPANGLER, JOSEPH RANKIN | 1656 | §103§112Other | Final Rejection | — | Pending | Feb 16, 2021 |
| 17055061 | SUBSTITUTION OF THE MESSENGER RNA CAP WITH TWO RNA SEQUENCES INTRODUCED AT THE 5-PRIME END THEREOF | Messenger Biopharma | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Final Rejection | 81d overdue | Pending | Nov 12, 2020 |
| 16789572 | MODULAR HARNESS FOR PATIENTS WITH POST-NEUROLOGIC INJURY | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | MILLER, CHRISTOPHER E | 3785 | §103 | Non-Final OA | — | Pending | Feb 13, 2020 |
| 15713347 | WIDESPREAD GENE DELIVERY TO MOTOR NEURONS USING PERIPHERAL INJECTION OF AAV VECTORS | Centre National De La Recherche Scientifique | SINGH, ANOOP KUMAR | 1632 | §112 | Non-Final OA | — | Pending | Sep 22, 2017 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial